AMG 333
Sponsors
Amgen
Conditions
Migraine
Phase 1
Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines
CompletedNCT01953341
Start: 2013-10-31End: 2014-11-30Updated: 2014-12-09
Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects
TerminatedNCT02132429
Start: 2014-05-31End: 2014-12-31Updated: 2015-04-01